Meyka Pro banner
NeuroPace, Inc.

NeuroPace, Inc. Fundamental Analysis (NASDAQ: NPCE)

NPCE●NASDAQ
HealthcareMedical - Devices
$12.77
$0.53(4.33%)
U.S. Market opens in 1h 29m

NeuroPace, Inc. Fundamental Analysis (NASDAQ: NPCE)

NeuroPace, Inc. (NASDAQ: NPCE) shows moderate financial fundamentals with a PE ratio of -22.27, profit margin of -19.34%, and ROE of -1.20%. The company generates $0.1B in annual revenue with strong year-over-year growth of 25.13%.

Key Strengths

Cash Position11.87%
PEG Ratio-0.54
Current Ratio4.94

Areas of Concern

ROE-1.20%
Operating Margin-15.26%
We analyze NPCE's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -104.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-104.7/100

We analyze NPCE's fundamental strength across five key dimensions:

Efficiency Score

Weak

NPCE struggles to generate sufficient returns from assets.

ROA > 10%
-19.71%

Valuation Score

Excellent

NPCE trades at attractive valuation levels.

PE < 25
-22.27
PEG Ratio < 2
-0.54

Growth Score

Excellent

NPCE delivers strong and consistent growth momentum.

Revenue Growth > 5%
25.13%
EPS Growth > 10%
29.03%

Financial Health Score

Moderate

NPCE shows balanced financial health with some risks.

Debt/Equity < 1
5.88
Current Ratio > 1
4.94

Profitability Score

Weak

NPCE struggles to sustain strong margins.

ROE > 15%
-119.68%
Net Margin ≥ 15%
-19.34%
Positive Free Cash Flow
No

Key Financial Metrics

Is NPCE Expensive or Cheap?

P/E Ratio

NPCE trades at -22.27 times earnings. This suggests potential undervaluation.

-22.27

PEG Ratio

When adjusting for growth, NPCE's PEG of -0.54 indicates potential undervaluation.

-0.54

Price to Book

The market values NeuroPace, Inc. at 36.54 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

36.54

EV/EBITDA

Enterprise value stands at -33.23 times EBITDA. This is generally considered low.

-33.23

How Well Does NPCE Make Money?

Net Profit Margin

For every $100 in sales, NeuroPace, Inc. keeps $-19.34 as profit after all expenses.

-19.34%

Operating Margin

Core operations generate -15.26 in profit for every $100 in revenue, before interest and taxes.

-15.26%

ROE

Management delivers $-1.20 in profit for every $100 of shareholder equity.

-1.20%

ROA

NeuroPace, Inc. generates $-19.71 in profit for every $100 in assets, demonstrating efficient asset deployment.

-19.71%

Following the Money - Real Cash Generation

Operating Cash Flow

NeuroPace, Inc. generates limited operating cash flow of $-11.31M, signaling weaker underlying cash strength.

$-11.31M

Free Cash Flow

NeuroPace, Inc. generates weak or negative free cash flow of $-11.68M, restricting financial flexibility.

$-11.68M

FCF Per Share

Each share generates $-0.34 in free cash annually.

$-0.34

FCF Yield

NPCE converts -2.64% of its market value into free cash.

-2.64%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-22.27

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.54

vs 25 benchmark

P/B Ratio

Price to book value ratio

36.54

vs 25 benchmark

P/S Ratio

Price to sales ratio

4.42

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

5.88

vs 25 benchmark

Current Ratio

Current assets to current liabilities

4.94

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-1.20

vs 25 benchmark

ROA

Return on assets percentage

-0.20

vs 25 benchmark

ROCE

Return on capital employed

-0.19

vs 25 benchmark

How NPCE Stacks Against Its Sector Peers

MetricNPCE ValueSector AveragePerformance
P/E Ratio-22.2730.72 Better (Cheaper)
ROE-119.68%561.00% Weak
Net Margin-19.34%7023.00% Weak
Debt/Equity5.880.51 Weak (High Leverage)
Current Ratio4.945.76 Strong Liquidity
ROA-19.71%-161.00% (disorted) Weak

NPCE outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews NeuroPace, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-17.53%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

70.00%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

82.72%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ